Efficacy

Blenrep (belantamab mafodotin-blmf) for Multiple Myeloma

Blenrep, with the active ingredient belantamab mafodotin-blmf, is a novel therapeutic agent approved for the treatment of multiple myeloma in patients who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The efficacy of Blenrep was demonstrated in a pivotal multicenter, open-label, single-arm study known as DREAMM-2. Patients treated with Blenrep showed a clinically meaningful overall response rate (ORR), indicating a reduction in tumor burden in a significant proportion of the treated population.

The primary efficacy outcome measure was the ORR, which included partial response or better. The study results showed that a substantial percentage of heavily pre-treated patients achieved a partial response or better, which is notable given the refractory nature of their disease. The median duration of response (DOR) was also observed to be encouraging, suggesting that Blenrep can provide a period of disease control in patients with limited treatment options.

Tecvayli (teclistamab-cqyv) for Multiple Myeloma

Tecvayli, also known as teclistamab-cqyv, is a bispecific antibody that targets both CD3 on T cells and BCMA on myeloma cells, designed to redirect T cells to induce the killing of tumor cells. It has shown promise in clinical trials for the treatment of relapsed or refractory multiple myeloma. The efficacy of Tecvayli was evaluated in a phase 1/2 study, which demonstrated an ORR that was considered significant in patients who had previously undergone multiple lines of therapy, including those who were refractory to other standard treatments.

Patients treated with Tecvayli showed responses that were deep and durable, with a notable percentage achieving very good partial response or better. The median DOR, progression-free survival (PFS), and overall survival (OS) data from the study indicated that Tecvayli could offer a new therapeutic option for patients with advanced multiple myeloma. The effectiveness of Tecvayli highlights the potential of bispecific antibodies in the treatment landscape of multiple myeloma, particularly for patients who have exhausted other available therapies.